Hepatitis C virus (HCV)

In 2021, DNDi completed development of a simple-to-use, affordable cure for HCV. Ravidasvir, a direct-acting antiviral (DAA), can cure the disease in 12 to 24 weeks when used with sofosbuvir. The first all-oral HCV treatment to be developed through South–South collaboration, ravidasvir acts as both a powerful new therapeutic option, and as a market shaper to bring down the cost of other life-saving HCV drugs in countries where they are priced out of reach. Alongside the development of ravidasvir, DNDi piloted new strategies to link patients to life-saving treatment and care. Through its work with allies in the Hepatitis C Partnership for Control and Treatment (Hepatitis C PACT), these strategies are now being replicated in pilot projects in Asia and Latin America.